Log In
BCIQ
Print this Print this
 

topical taladegib (topical LY2940680)

  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
DescriptionSmall molecule antagonist of smoothened (SMO) and inhibitor of sonic hedgehog homolog (SHH)
Molecular Target Smoothened (SMO) ; Sonic hedgehog homolog (SHH)
Mechanism of ActionSmoothened antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationBasal cell carcinoma (BCC)
Indication DetailsTreat treat superficial and nodular basal cell carcinoma (BCC)
Regulatory Designation
PartnerIgnyta Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$53.0M

$2.0M

$38.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/08/2015

$53.0M

$2.0M

$38.0M

Get a free BioCentury trial today